VALNEVA published its Annual Financial Report 2014

LYON, France, April 29, 2015 (GLOBE NEWSWIRE) -- Valneva SE ("Valneva"), a leading pure play vaccines biotech company, announced today that it has published its Annual Financial Report for the year ended on December 31, 2014, containing:

  • the Statutory Financial Statements (including the amount of fees paid to the Statutory Auditors);
  • the Consolidated Financial Statements as already published on March 20, 2015;
  • an excerpt of the 2014 Management Board Annual Report (including a description of the share buy-back program); and
  • the 2014 Report of the Chairman of the Supervisory Board on the preparation and organization conditions of the Supervisory Board and the internal control procedures implemented by the Company, together with the corresponding Auditors' Report.

The document is available on the "Investors & media" page of the company's corporate website (, under the heading "Investor Information" / "Annual Reports".

Contacts Valneva SE:

Florence Hocdée- Leroy

T: +33 (0)228 07 37 10

M: +33 642 04 42 14

Teresa Pinzolits

T : +43-1-206 20-1116

M: +43 676 845567357

About Valneva SE

Formed in 2013 through the merger of Intercell AG and Vivalis SA, Valneva is a biotechnology company specialized in the development, manufacture and commercialization of innovative vaccines with a mission to protect people from infectious diseases. The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

Valneva's portfolio includes two commercial vaccines for travelers: one for the prevention of Japanese encephalitis (IXIARO®) and the second (DUKORAL®) indicated for the prevention of and protection against Travelers' Diarrhea caused by ETEC (Enterotoxigenic Escherichia coli) and/or Cholera. The Company has proprietary vaccines in development including candidates against Pseudomonas aeruginosa, Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company's value proposition and include vaccines being developed using Valneva's innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant).

Valneva has its registered seat in Lyon, France, is listed on Euronext-Paris and the Vienna Stock Exchange and operates out of France, Austria, Scotland and Sweden with approximately 400 employees. More information is available at

Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing and completion of research, development and clinical trials for product candidates, the ability to manufacture, market, commercialize and achieve market acceptance for product candidates, the ability to protect intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing the information in these materials as of the date of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Valneva PR Annual Financial Report 2014